Cipla FY26 revenue hits record; shares jump 5% on NSE

Stock jumps after record FY26 revenue

Shares of Cipla rose sharply on Wednesday, May 13, after the drugmaker said it posted its highest-ever yearly revenue in fiscal 2026. The stock climbed nearly 5% to an intraday high of ₹1,353.80 on the NSE. Around 13:45 PM, it traded at ₹1,349.40, up 4.5% versus the previous close of ₹1,292.30. The move came even as Cipla reported a weaker-than-expected March-quarter profit and a sharp drop in operating margins. The company’s India business remained strong, while North America weighed on the quarter. Investors appeared to balance the record annual revenue milestone against the near-term earnings pressure. The stock was still up 4.23% in the afternoon, according to the Reuters update.

March-quarter numbers show margin pressure

For the quarter ended March 31, 2026 (Q4FY26), Cipla reported income from operations of ₹6,541 crore. This was down 2.8% year-on-year from ₹6,730 crore in the same quarter last year. Earnings before interest, tax, depreciation and amortisation (Ebitda) fell 35.17% to ₹997 crore from ₹1,538 crore a year earlier. Ebitda margin dropped to 15.2% from 22.8%, reflecting a sharp contraction in profitability during the quarter. Profit after tax (PAT) came in at ₹555 crore, down 54.6% from ₹1,222 crore in March 2025. Reuters reported the consolidated net profit of 5.55 billion rupees (₹555 crore) missed analysts’ average estimate of 7.05 billion rupees (₹705 crore), based on LSEG data. Revenue from operations of 65.41 billion rupees (₹6,541 crore) also came in below the average expectation of 67.49 billion rupees (₹6,749 crore).

North America slowdown offsets domestic demand

Cipla’s quarter was hurt by a sales decline in North America, which Reuters described as the key factor behind the revenue miss. Revenue from India, which Reuters called Cipla’s biggest market by sales, rose 15% to 30.07 billion rupees (₹3,007 crore). In contrast, revenue from North America fell 26% to 14.14 billion rupees (₹1,414 crore). Reuters said the India and North American markets together account for roughly three-fourths of Cipla’s total sales, making weakness in the US hard to offset in the near term. The company also highlighted, in its exchange filing, that its One India business grew 15% year-on-year with all three segments delivering double-digit growth during the quarter. It said Branded Prescription sustained momentum in key chronic therapies, Trade Generics continued steady growth, and anchor brands of the Consumer Health Business kept expanding.

Costs rise; impairment adds to pressure

Cost pressures were another key theme in the quarter. Total expenses rose nearly 8.5% year-on-year to 18.82 billion rupees (₹1,882 crore), Reuters reported. The company also recorded an impairment charge of about 420.2 million rupees (₹42.02 crore) on its associates, adding to the cost load. Cipla said it invested ₹509 crore in research and development during the quarter, equal to 7.8% of sales, driven by product filings and development work. The combination of lower revenue in North America and a higher cost base contributed to the steep fall in Ebitda and margins. These numbers help explain why the quarterly profit fell despite strong domestic growth.

FY26 annual performance: revenue record, mixed profitability

Despite the soft March quarter, Cipla reported record annual revenue for FY26. Revenue from operations for the full year stood at ₹28,163 crore, up 2.23% from ₹27,548 crore in FY25. The company described FY26 as its highest-ever yearly revenue, noting strength in core businesses even as certain markets faced near-term challenges. Ebitda for FY26 was ₹5,925 crore, down 17% from ₹7,128 crore in FY25. Profit after tax for FY26 was ₹5,273 crore versus ₹3,879 crore in the previous fiscal, as stated in the provided results summary. The company also said its One India business surpassed the ₹12,500 crore annual revenue milestone. This combination of record revenue and weaker full-year Ebitda highlights a year where topline resilience did not fully translate into operating profitability.

Business highlights: India, US and Africa

Cipla said its North America business delivered quarterly revenue of $155 million, supported by demand in its differentiated portfolio and a steady base business. For the full year, the company stated that its US business posted annual revenue of $180 million, again supported by demand in differentiated products and a steady base business. In One Africa, Cipla recorded annual growth of 7% year-on-year in USD terms, driven by performance across key markets. These disclosures underline the company’s focus on multiple geographies, with India remaining a key growth engine in FY26. But the Reuters report also pointed to “sharp weakness” in the U.S. business during the quarter, which weighed on consolidated results. The geographic split explains why the market reaction could be positive on the annual milestone while acknowledging quarter-level stress.

Dividend announcement and trading context

Cipla declared a dividend of ₹13 per share, according to Reuters. The stock reaction came alongside this shareholder payout announcement, even as the company posted lower quarterly profit. Reuters also noted Cipla shares have fallen about 14.3% so far this year, providing context for the day’s rebound. The intraday jump took the price close to ₹1,350 levels, materially above the previous close of ₹1,292.30. The move suggests investors were responding to a mix of factors: the record FY26 revenue headline, strength in India, and the dividend, while still digesting the US slowdown and margin contraction.

Key numbers at a glance

Why the FY26 record matters, despite Q4 weakness

Cipla’s FY26 revenue of ₹28,163 crore sets a new annual high for the company, and management linked it to the strength of core businesses. The One India business crossing ₹12,500 crore in annual revenue indicates the domestic franchise remains a central pillar for growth. At the same time, the quarter highlighted how dependent consolidated performance can be on North America, given its weight in the sales mix described by Reuters. The earnings miss versus analyst estimates, combined with the steep Ebitda margin decline to 15.2%, shows profitability can be volatile when costs rise and a key geography slows. Investors will likely track whether the US base business stabilises and whether cost pressures ease, especially after the impairment and the higher expense line flagged in the Reuters report.

What to watch next

Cipla’s results put the spotlight on the balance between steady India growth and cyclical swings in North America. The company has signalled continued investment in filings and development through its quarterly R&D spend of ₹509 crore. Near term, markets may watch for updates on North America demand trends and how management addresses the margin compression seen in Q4FY26. With the dividend of ₹13 per share declared, shareholder returns are also part of the narrative alongside operating performance. Further disclosures in subsequent filings or management commentary will be key to understanding whether Q4 was a temporary dip or part of a longer adjustment in the company’s geographic mix.